A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain

A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain

Publication date: Jul 10, 2019

A prospective, multicenter, self-control clinical trial aim to enroll 110 patients suffered from upper abdominal (liver, pancreas, stomach, etc.) cancers . Patients who have taken at least one opioid drug for pain for two weeks and still have a VAS pain scale greater than 6 will receive endovascular denervation (EDN). They will be followed up for 3 months. The VAS scales, quantity of analgesics as represented by morphine equivalent and quality of life scores will be compared before and after EDN. Safety parameters such as arterial deformation, embolism, infection, liver and kidney functions will also be monitored.

Concepts Keywords
Analgesics Pain
Aorta Hepatology
Breast Feeding Medical specialties
Clinical Trial Medicine
Coagulation RTT
Deformation Clinical medicine
Embolism Denervation
Endovascular Hepatocellular carcinoma
Infection Liver cancer
Informed Consent
Kidney
Liver
Morphine
Neoplasms
Opioid
Pain
Pancreas
Shanghai
Stomach
Stroke
Systemic Infection

Semantics

Type Source Name
disease MESH Cancer
disease DOID Cancer
gene UNIPROT CD5L
gene UNIPROT CD69
gene UNIPROT DNMT1
gene UNIPROT RNASE2
drug DRUGBANK Morphine
disease MESH embolism
disease MESH infection
disease MESH Bleeding
gene UNIPROT EHD1
disease MESH stroke
disease DOID stroke
disease DOID TIA
gene UNIPROT NR4A2
gene UNIPROT ALG3
disease MESH Liver Neoplasms

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *